Member Companies

Rebiotix Inc.

About Rebiotix

Rebiotix Inc, which is part of the Ferring Pharmaceuticals Group, is a late-stage clinical microbiome company focused on harnessing the power of the human microbiome to revolutionize the treatment of debilitating diseases. Rebiotix possesses a deep and diverse clinical pipeline, with its lead drug candidate, RBX2660, in Phase 3 clinical development for the prevention of recurrent Clostridium difficile (C. diff) infection. RBX2660 has been granted Fast Track status, Orphan Drug and Breakthrough Therapy designation from the FDA for its potential to prevent recurrent C. diff infection. Rebiotix’s clinical pipeline also features RBX7455, a lyophilized non-frozen, oral capsule formulation, which is currently moving into a Phase 2 IND trial for the prevention of recurrent C. diff infection having completed an investigator sponsored Phase 1 study. In addition, Rebiotix is targeting several other disease states with drug products built on its pioneering Microbiota Restoration Therapy™ platform. The MRT™ platform is a standardized, stabilized drug technology that is designed to rehabilitate the human microbiome by delivering a broad consortium of live microbes into a patient’s intestinal tract via a ready-to-use and easy-to-administer format.

Target Indications
Recurrent C. diff prevention
VRE Elimination
Pediatric Ulcerative Colitis
Multi-drug Resistant UTI
Hepatic Encephalopathy

Lee Jones – Founder, President, and Chief Executive Officer
Dale N. Gerding, M.D., MACP, FIDSA, FSHEA – Chief Medical Officer
Ken F. Blount, Ph.D. – Chief Scientific Officer
Edward S. Burd, Ph.D. – Head of Regulatory Affairs
Nancy Timm, VP of Finance and Operations

Twitter: @Rebiotix

Seres Therapeutics

About Seres

Seres Therapeutics, Inc. (Nasdaq: MCRB) is a leading microbiome therapeutics platform company developing a novel class of biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome, where the state of bacterial diversity and function is imbalanced. Seres’ SER-287 program has obtained Fast Track and Orphan Drug designation from the U.S. Food and Drug Administration and is being evaluated in a Phase 2b study in patients with active mild-to-moderate ulcerative colitis. Seres’ SER-109 program has obtained Breakthrough Therapy and Orphan Drug designations from the FDA and is in Phase 3 development for recurrent C. difficile infection. Seres is also developing SER-401 in a Phase 1b study in patients with metastatic melanoma.
Target Indications
C. difficile
Ulcerative Colitis
Inflammatory bowel disease

Eric Shaff – President, Chief Executive Officer
John Aunins, Ph.D. – Executive Vice President, Bioprocess & Manufacturing and Chief Technology Officer
Thomas J. DesRosier, Esq. – Executive Vice President, Chief Legal Officer and Secretary
Matthew Henn, Ph.D. – Executive Vice President, Chief Scientific Officer
Lisa von Moltke, M.D. – Executive Vice President, Chief Medical Officer
Jim Weston – Senior Vice President, Regulatory Affairs

Twitter: @SeresTX

Siolta Therapeutics

About Siolta

Siolta Therapeutics is a clinical-stage biotech company on a mission to alleviate the suffering of millions impacted by chronic inflammatory diseases through novel microbiome-based medicines. Siolta leverages its deep knowledge of the developing infant gut microbiome and its role in promoting immune tolerance to develop targeted microbial therapeutics and companion diagnostics for the prevention and treatment of inflammatory diseases. The company’s blended expertise from microbiology, immunology, and bioinformatics supports the development of a multifaceted platform, integrating ecosystems approaches and precision medicine concepts to advance the future of medicine. Currently focused on the clinical development of their lead product for the prevention and treatment of allergic asthma, Siolta’s holistic, microbiome-based strategy represents a new frontier in the pursuit of tailored, clinically differentiated microbial therapeutics.

Target Indications
Allergic Asthma
Food Allergy
Atopic Dermatitis
Allergic Rhinitis
Prevention of Allergic Disease
Metabolic Disease
Post-Antibiotic Recovery

Nikole Kimes, Ph.D. – Founder, Chief Executive Officer
Richard Shames, M.D. – Consulting CMO
Ricardo Valladares, Ph.D. – Vice President of Research and Development
Susan Lynch, Ph.D. – Founder, Member of the Board of Directors
Samir Kaul, MBA – Member of the Board of Directors

Twitter: @SioltaThera


About Takeda

Takeda Pharmaceutical Company Limited is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Rare Diseases and Neuroscience. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. For more information, visit

Microbiome-related Target Indications
Inflammatory bowel diseases
Crohn’s disease
Ulcerative Colitis
Complications of Liver disease

Twitter: @TakedaPharma

Vedanta Biosciences

About Vedanta

Vedanta Biosciences is developing a new category of therapies for immune-mediated and infectious diseases based on rationally defined consortia of human microbiome-derived bacteria. Vedanta Biosciences is a leader in the microbiome field with capabilities and deep expertise to discover, develop, and manufacture live bacteria drugs. These include what is believed to be the largest collection of human microbiome-associated bacterial strains, a suite of proprietary assays to select pharmacologically potent strains, vast proprietary datasets from human interventional studies, and facilities for cGMP-compliant manufacturing of rationally-defined bacterial consortia in powder form.

Vedanta Biosciences’ pioneering work, in collaboration with its scientific co-founders, has led to the identification of human commensal bacteria that induce a range of immune responses – including induction of regulatory T cells, CD8+ T cells, and Th17 cells, among others. These advances have been published in leading peer-reviewed journals including Science (multiple), Nature (multiple), Cell and Nature ImmunologyVedanta Biosciences has harnessed these biological insights and its capabilities to generate a pipeline of programs in infectious disease, autoimmune disease, allergy, and immune-oncology.

Target Indications
C. difficile
Inflammatory Bowel Disease
Food Allergy
Multi-drug Resistant Organisms
Cancer Immunotherapy

Bernat Olle, Ph.D. – Chief Executive Officer
Dan Couto – Chief Operations Officer
Jeffrey Silber, M.D. – Chief Medical Officer
Lorraine Hughes, M.S. – VP, Clinical Operations
Nancy Wilker, Ph.D., J.D. – VP, Head of Legal Affairs and IP

Twitter: @VedantaBio